Giulia Galli

Università degli Studi di Firenze, Firenze, Toscana, Italy 
memory, face
"Giulia Galli"
Mean distance: 18.9 (cluster 23)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Bhang J, Ma H, Yim D, et al. (2021) First-Principles Predictions of Out-of-Plane Group IV and V Dimers as High-Symmetry, High-Spin Defects in Hexagonal Boron Nitride. Acs Applied Materials & Interfaces
Monzani D, Petrocchi S, Oliveri S, et al. (2021) Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing Weighting. Frontiers in Medicine. 8: 689114
Manglaviti S, Brambilla M, Signorelli D, et al. (2021) Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. Clinical Lung Cancer
Vo H, Zhang S, Wang W, et al. (2021) Lessons learned from first-principles calculations of transition metal oxides. The Journal of Chemical Physics. 154: 174704
Barry E, Burns R, Chen W, et al. (2021) Advanced Materials for Energy-Water Systems: The Central Role of Water/Solid Interfaces in Adsorption, Reactivity, and Transport. Chemical Reviews
Dong SS, Govoni M, Galli G. (2021) Machine learning dielectric screening for the simulation of excited state properties of molecules and materials. Chemical Science. 12: 4970-4980
Occhipinti M, Brambilla M, Galli G, et al. (2021) Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine. 11
Rozsa V, Galli G. (2021) Solvation of simple ions in water at extreme conditions. The Journal of Chemical Physics. 154: 144501
Prelaj A, Bottiglieri A, Proto C, et al. (2021) Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. European Journal of Cancer (Oxford, England : 1990)
Prelaj A, Pircher CC, Massa G, et al. (2021) Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers. 13
See more...